anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Posture is defined as the arrangement or orientation of body parts in relation to each other. This alignment depends on the effect of gravity, muscle tension and the integrity of the bony structures. Posture disorders, which are now common among healthy young adults, are caused by a number of factors that have emerged in combination with the effects of modern lifestyle.In this study, it was aimed to examine the effect of an 8-week artificial intelligence-based structured exercise program in healthy adults. It performs measurements on frontal and lateral images of the individual in normal posture Photo of a participant showing how the Posture Screen Mobile app evaluates the horizontal tilt and inclination of the head, shoulders and hips from a frontal view.The craniovertebral angle (CVA) is a measurement of upper cervical posture obtained by calculating the angle between the ear tragus and a horizontal line passing through the spinous process of C7). KVA will be done with Posture Screen Mobile Phone application.Thoracic kyphosis is the anteroposterior curve of the thoracic spine in the sagittal plane and is defined using the Cobb angle.Thoracic kyphosis is the hunching of the spine in the upper back into an extreme external curve due to deformity.Lumbar lordosis is the natural inward curve of the spine in the lumbar region. It is an important anatomical feature that maintains the height of the discs in front of the lumbar vertebrae and ensures the stability of the spine.An artificial intelligence application called "Musclewiki" will be used for healthy adults to continue their exercise training at home. For 8 weeks, exercise will be practiced 3 times a week in the company of a physiotherapist, accompanied by a physiotherapist through artificial intelligence.
Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
Particles with particle size of not > 10 mu m, comprise: (a) uncharged polyacrylate; (b) cationic polyacrylate, which carries positively charged functional groups; (c) at least one active substance; and (d) optionally other polymers, auxiliaries or additives. An independent claim is also included for producing the particles, comprising (i) preparing a solution of the components (a)-(d) in a small extent with water-miscible solvent or solvent mixture, (ii) dispersing the solution in an aqueous phase, optionally containing additives and solvent or solvent mixture up to saturation to produce a fine, stable emulsion, and (iii) removing the solvent or solvent mixture from the emulsion droplets by evaporation (solvent evaporation process) to obtain an aqueous suspension, or spray-drying to obtain a dry powder; and #an agent comprising the particles. ACTIVITY : Antiparasitic; Acaricide. The acaricide activity of the agent was tested in vivo in beagle-type dogs (21-30 months old and weighing 8.8-15.5 kg) by spraying the agent containing flumethrin particles (15%) and polymethyl methacrylate on whole body of the dog. The results showed that agent reduces the number of ticks after 50 study days (0) compared to untreated dogs (14). MECHANISM OF ACTION : None given.
Progressive myoclonic epilepsy type 1 (EPM1) is an autosomal recessive disorder, also known as Unverricht-Lundborg disease (ULD). EPM1 patients suffer from photo-sensitive seizures, stimulus-sensitive myoclonus, nocturnal myoclonic seizures, ataxia and dysarthria. In addition, cerebral ataxia and impaired GABAergic inhibition are typically present. EPM1 is caused by mutations in the Cystatin B gene (CSTB). The CSTB protein functions as an intracellular thiol protease inhibitor and inhibits Cathepsin function. It also plays a crucial role in brain development and regulates various functions in neurons beyond maintaining cellular proteostasis. These include controlling cell proliferation and differentiation, synaptic functions and protection against oxidative stress, likely through regulation of mitochondrial function. Depending on the differentiation stage and status of neurons, the protein localizes either to the cytoplasm, nucleus, lysosomes or mitochondria. Further, CSTB can also be secreted to the extracellular matrix for interneuron rearrangement and migration. In this review, we will review the various functions of CSTB in the brain and discuss the putative pathophysiological mechanism underlying EPM1.
Long COVID, or post-acute sequelae of COVID-19 (PASC), represents a complex condition with persistent symptoms following SARS-Cov-2 infection. The symptoms include fatigue, dyspnoea, cognitive impairment, decreased quality of life in variable levels of severity. Potential mechanisms behind long COVID include vascular damage, immune dysregulation and viral persistence. Diagnosing long COVID involves medical evaluation by multidisciplinary team and assessment of persistent symptoms with scoring systems in development. Treatment strategies are symptom-focused, encompassing multidisciplinary care, rehabilitation and tailored exercise programmes. Pulmonary rehabilitation, an effective and critical component of long COVID management, has shown promise, particularly for patients with respiratory symptoms such as dyspnoea. These programmes, which combine exercise, breathing techniques, education and psychological support, improve symptoms, quality of life and overall recovery. Innovative technologies, such as telemedicine, wearable devices, telerehabilitation, are transforming long COVID management. Telemedicine facilitates consultations and interventions, eliminating healthcare access barriers. Wearable devices enable remote and continuous monitoring of patients during their rehabilitation activities. Telerehabilitation has proven to be safe and feasible and to have high potential for COVID-19 recovery. This review provides a concise overview of long COVID, encompassing its definition, prevalence, mechanisms, clinical manifestations, diagnosis and management approaches. It emphasizes the significance of multidisciplinary approach in diagnosis and treatment of long COVID, with focus on pulmonary rehabilitation and innovative technology advances to effectively address the management of long COVID.
Despite increased use of insulin pumps and continuous glucose monitors (CGM) for pediatric type 1 diabetes (T1D) management and research studies showing benefits from the use of these devices, real-world glycemic control among youth with T1D has worsened in recent years. Although greater youth and parental diabetes knowledge is associated with better glycemic control, education alone is not sufficient to bring about the behavioral changes needed to improve outcomes in T1D. Psychoeducation recognizes the need to blend educational and behavioral approaches, including problem-solving and goal-setting, to support parents in developing optimal T1D management approaches. There are currently a lack of effective standardized tools to support patients and families in developing the knowledge and behavioral strategies needed to optimize the use of diabetes technologies. The development of innovative family-centered psychoeducational tools addressing both behavior and knowledge will help to realize the full potential of diabetes technologies to improve glycemic control and quality of life while ultimately preventing or delaying the development of both acute and long-term complications of T1D.

Interviews with parent-child dyads and diabetes clinicians will be used to identify the unmet parental psychoeducational needs regarding insulin pumps and CGM. These results will inform the use of instructional design to adapt an existing app-delivered diabetes technology curriculum to meet the specific needs of parents of children with T1D. Finally, the investigators will assess the feasibility and acceptability of this novel family-facing psychoeducational app-delivered intervention in a non-randomized pilot study.
The present application may provide a computing system for measuring and monitoring patient biomarkers for detecting or predicting weight loss post-operative complications. The weight loss post-operative complications may be predicted or detected by comparing the measured/processed patient biomarker data to a corresponding determined threshold. The comparison of the measured/processed patient biomarker data with the corresponding threshold may be performed in association with a background context. The context may be based on at least one of a weight-loss surgical restoration timeline, at least one situational attribute, or at least one environmental attribute. Notification messages associated with predicted or detected weight loss post-operative complications may be sent (e.g., in real-time) to a patient device or healthcare worker device. The notification message may be supplemented by a severity level message.
Control group are women aged 18-45 surgically verified not to have endometriosis. At study entry, we will collect morning blood samples.
PURPOSE: A method of treating bipolar disorder in humans using xanomeline is provided, wherein xanomeline may address the long felt need for treatments having an acceptable safety profile and provide effective relief to the patient suffering from bipolar disorder. CONSTITUTION: A method for treating bipolar disorder in humans comprises of administering to a human in need thereof, an effective amount of a compound of Formula I. Dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. When the compound is delivered transdermally, it is preferred that the effective amount is from about 10mg to about 100mg per day delivery of base compound. It is especially preferred that such patch delivers an effective amount for about one to seven days.
PURPOSE:To provide the titled preparation by compounding lecithin to elastase. CONSTITUTION:A stabilized elastase preparation resistant to the lowering of the activity can be produced by mixing 1pt.wt. of elastase with 0.1-10pts.wt., preferably 0.5-3pts.wt. of a lecithin (e.g. soybean lecithin, yolk lecithin, etc.) and 0.5-15pts.wt., preferably 1-5pts.wt. of cyclodextrin. It can be used in the form of powder, tablet, capsule, emulsion for injection, etc., and is administered orally or parenterally at a dose some as that of the conventional elastese preparation. The preparation is stable to heat and moisture (water) and resistant to the lowering of the activity, and has excellent storage stability, etc.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a hesperetin-7-β-maltoside and to provide uses thereof.  <P>SOLUTION: The method for producing the hesperetin-7-β-maltoside is characterized as follows. Hesperidin is reacted with an enzyme having an α-1,6-rhamnosidase activity to remove rhamnose. The resultant 7-β-D-monoglucosyl hesperetin is reacted with a glycosyltransferase in the presence of starch or dextrin to add one or more α-D-glucoses. A method for producing a hesperetin glycoside composition containing the hesperetin-7-β-maltoside is characterized as follows. The resultant addition product is reacted with a hydrolase to reduce the average number of added glucoses. Thereby, the average number of added glucoses is regulated to 1.5-3.0 based on the 7-β-D-monoglucosyl hesperetin. A method for improving the water solubility of a sparingly water-soluble substance comprises making the sparingly water-soluble substance selected from the hesperidin, the 7-β-D-monoglucosyl hesperetin, hesperetin, rutin, naringin and isoflavone coexist with the hesperetin-7-β-maltoside.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to a stable photo-responsive Pickering emulsion with photosensitive POSS hybrid particles as an emulsifying agent and a preparation method. Octa(gamma-chloropropyl) POSS serves as an initiator, an azobenzene-containing double-bond compound serves as a monomer, and the photosensitive POSS hybrid particles are prepared through the atom transfer radical polymerization (ATRP) method. The water-in-oil (W/O) type Pickering emulsion is obtained through shear field emulsification. The method is simple, feasible, high in operability and capable of being applied to the field of cosmetics. Through external stimuli, the emulsion is demulsified and release moisture of an internal phase so that skin can be moistened or prevented from being harmed by ultraviolet rays. The emulsion can also be applied to the field of drug sustained release, and through UV irradiation, controllable release of internal phase medicine is achieved. Accordingly, the emulsion can be widely used in the fields such as cosmetics, biology and pesticide delivery, and has very good application and popularization value.
PURPOSE:To obtain an antiallergic agent, containing 4,5-dihydro-4,5-dioxo-1H- pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid or salts thereof, having low toxicity and effective against various allergic diseases. CONSTITUTION:An antiallergic agent containing 4,5-dihydro-4,5-dioxo-1H- pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid (hereinafter abbreviated to PQQ) or salts thereof as an active ingredient. Metal salts with Na, K, Ca, Mg, Al, etc., or salts with amino acids, e.g. lysine, et., are cited as the above-mentioned salts. The PQQ is economically obtained in a large amount by cultivating a microorganism belonging to lactic acid bacteria, yeasts, imperfect fungi, etc. in addition to a chemical synthetic method. The above-mentioned antiallergic agent is effective against bronchial asthma, allergic rhinitis, etc. The PQQ or salts thereof in a normally effective amount can be blended with a pharmaceutically conventional medicinal additives and administered in various dosage forms.
510,931. Hop and malt extracts and compositions. WOOD, L. D. Sept. 27, 1938, No. 28078. [Class 14 (ii)] [Also in Group III] A hop extract or concentrate is mixed with malt syrup and the mixture emulsified as in a colloid mill. The hop extract is preferably made by extracting the hops with acetone and evaporating the acetone under vacuum. Extracts are standardized as to liquidity, specific gravity &c. by the addition of alcohol, glyceryl laurate and tannin. The extract from old, perhaps rancid, hops is improved by treating it with activated carbon which may be made from the vegetable fibrous material of the hops residue.
KCNB1-associated encephalopathy is characterized by intellectual disability (ID), autism spectrum disorder and epilepsy. Specific treatments are still lacking. We describe a 12-year-old boy with severe ID and treatment-resistant seizures due to a pathogenic KCNB1 variant. His EEG showed a CSWS pattern. Aged 11, he started treatment with highly purified cannabidiol (CBD) and has been seizure free for 18 months, with significant EEG and social skills improvements. This suggests CBD may benefit CSWS, likely due to its anti-inflammatory properties. Some preclinical studies also indicate CBDs interact with voltage-gated channels, leading us to speculate its possible role for treating KCNB1 related encephalopathy.
Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
The study will be a single center, pilot trial. It will be an open label, single-arm, non- controlled design. All HS kidney transplant recipients with Panel Reactive Antibodies (PRA) ≥ 30%, age 18 and older, requiring desensitization may be included in the study. Initial desensitization protocol for living donor (LD) or deceased donor (DD) includes Intravenous Immunoglobulin (IVIG) 2g/kg (\>70kg max 140g) given on day 0 (split over 2 days for peritoneal dialysis patients), rituximab 375mg/m2 (rounded to the nearest 100mg vial) given on day 15, and IVIG 2g/kg (\>70kg max 140g ) given on day 30. Recipients for LD or DD who are unresponsive to IVIG/ritux (after 2 months for LD and after 6 months for DD) will require PLEX 5-7 sessions followed by IVIG 2g/kg (\>70kg max 140g) and rituximab 375mg/m2. Patients will be receiving acetaminophen, antihistamine, and steroid as premedication for all infusions.

A total of 20 subjects will be enrolled in the study. Subjects will take part in the study until they are one year post-transplant. All subjects will require informed consent. At the time of screening, subjects will receive a physical exam and undergo lab testing. Alemtuzumab 30mg, will be administered subcutaneously to all subjects for induction immunosuppression immediately post-transplant. Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone. Patients will receive antimicrobial prophylaxis per Cedars-Sinai Medical Center (CSMC) protocol. Lab tests and physical exams for safety will take place according to the evaluation schedule below. Safety will be assessed by the reporting of serious adverse events.

Tacrolimus trough level, complete metabolic panel, liver function panel, complete blood count with differential, Donor Specific Antibodies (DSA), and urinalysis with culture will be assessed according to the evaluation schedule below. Subjects will complete the study at one year post-transplant. Consent may be withdrawn by the study participant at any time. The investigator may also withdraw the study participant at any time if there are any safety concerns.

Desensitization includes Intravenous Immunoglobulin (IVIG) 2g/kg (\>70kg max 140g) given on day 0 (split over 2 days for peritoneal dialysis patients), rituximab 375mg/m2 (rounded to the nearest 100mg vial) given on day 15, and IVIG 2g/kg (\>70kg max 140g ) given on day 30. Patients will require PLEX 5-7 sessions if they have received desensitization in the past. In this case, patients will receive PLEX daily x 5-7 sessions followed by IVIG 2g/kg (\>70kg max 140g) and rituximab 375mg/m2. Patients will be receiving acetaminophen, antihistamine, and steroid as premedication for all infusions.
A total of 9 Cantonese-speaking chronic post-stroke patients who are suffering from dysarthria was recruited and randomly divided into treatment group and sham group. For the treatment group, an anodal high-definition tDCS of 2 milliampere (mA) lasting for 15 minutes was delivered to the primary motor cortex (SM1) in 10 daily sessions during a 2-week period. For the sham tDCS group, the same setting of tDCS electrodes was applied on the scalp, but the stimulation only lasted for 30 sec in order to cause similar sensation on the scalp as the other group. Simultaneous to the tDCS stimulation, both groups will receive speech and voice therapy for 30 minutes.

An array of outcome measures reflecting speech production ability including acoustic, kinematic, perceptual and self-perceptual qualities was obtained before and after stimulation. It was anticipated that post-stroke dysarthric patients will see improvement in speech production after stimulation. The results provided important insights into the effects of tDCS on articulatory movement in individuals with dysarthria post-stroke.
BACKGROUND: The concept of metabolically obese, normal weight (MONW) has emerged to describe individuals with a normal body mass index (BMI) who are at a relatively high risk of chronic diseases. However, BMI itself is a suboptimal index for the assessment of the health risks associated with visceral fat. The triglyceride-glucose (TyG) index is considered to be a reliable and cost-effective marker of insulin resistance. Therefore, in the present study, we aimed to determine the TyG index cut-off values that could be used to define MONW in older people and to determine the usefulness of these values for the prediction of chronic diseases.
METHODS: A total of 4,721 participants in the Korea National Health and Nutritional Examination Survey who were ≥ 60 years of age and did not have underweight or obesity were included. MONW was defined using the criteria for metabolic syndrome (MS), and the TyG index was calculated on the basis of the fasting plasma triglyceride and glucose concentrations. Chronic diseases, including T2DM, hypertension, and non-alcoholic fatty liver disease (NAFLD), were diagnosed.
RESULTS: The prevalence of MS increased from the lowest to the highest TyG index tertile. The cut-off values of the TyG index for MONW were calculated as 8.88 and 8.80 for males and females, respectively. MONW, defined using these cut-off values, was associated with high odds ratios for NAFLD, T2DM, and hypertension in both males and females.
CONCLUSIONS: The TyG index cut-off values calculated in the present study can be used to discriminate individuals with MONW from other older individuals without obesity and to predict the risk of chronic diseases. These findings show that the TyG index is an effective and cost-efficient method of assessing the risk of chronic diseases in people with MONW.
Risk Summary 

There is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. Systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clobetasol propionate foam and any potential adverse effects on the breastfed infant from clobetasol propionate foam or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clobetasol propionate foam directly to the nipple and areola to avoid direct infant exposure.